Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Pharmacoepidemiology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1499723

This article is part of the Research Topic Pharmacoepidemiology in Chronic Diseases View all 6 articles

The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis

Provisionally accepted
Feng Zhao Feng Zhao 1Yu Lan Chen Yu Lan Chen 1Haina Liu Haina Liu 1Lei Jin Lei Jin 2Xin Feng Xin Feng 3Bingbing Dai Bingbing Dai 4Meng Chen Meng Chen 1Qiao Wang Qiao Wang 1Yuxin Yao Yuxin Yao 1Ruobing Liao Ruobing Liao 1Junyi Zhao Junyi Zhao 1Bingjia Qu Bingjia Qu 1Ying Song Ying Song 1Lingyu Fu Lingyu Fu 1*
  • 1 The First Affiliated Hospital of China Medical University, Shenyang, China
  • 2 Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
  • 3 First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, China
  • 4 Dalian Municipal Central Hospital, Dalian, Liaoning Province, China

The final, formatted version of the article will be published soon.

    Objectives: This research aims to reveal the mechanisms of the effect of the Paraoxonase 1 (PON1) gene on response to leflunomide (LEF) in rheumatoid arthritis (RA) patients, in terms of single nucleotide polymorphism (SNP), DNA methylation levels.Methods: A total of 240 RA patients enrolled were categorized into the good response group and the non-response group according to the difference in DAS28 scores between baseline and six months after LEF administration. The identified LEF-response cytosine-phosphate-guanines (CpGs) island(cg17330251) and its internal SNPs (rs705379, etc.) located at the PON1 promoter were detected by Sanger sequencing and methyl target sequencing.Results: A total of 12 CpG sites at cg17330251 could be identified in our RA patients. There were significant difference between the responders and non-responders in nine CpG sites: cg17330251_2, cg17330251_3, cg17330251_4, cg17330251_6, cg17330251_7, cg17330251_8, cg17330251_9, cg17330251_10, cg17330251_12, (OR (95CI%) = 0.492 (0.250, 0.969), 0.478 (0.243, 0.940), 0.492 (0.250, 0.969), 0.461 (0.234, 0.907), 0.492 (0.250, 0.969), 0.437 (0.225, 0.849), 0.478 (0.243, 0.941), 0.421 (0.212, 0.836), 0.424 (0.213, 0.843), P < 0.05, respectively). At all these nine CpG sites, the proportions of low methylation levels in the responders were higher than those in the nonresponders (P < 0.05). In a dominant model, there was a significant difference in rs705379 wildtype CC and mutant genotypes (CT+TT) between the responders and non-responders (P < 0.05). The average methylation level of 12 CpG sites was lowest in rs705379-CC (median 0.229, IQR 0.195-0.287), then rs705379-CT (median 0.363, IQR 0.332-0.395), and rs705379-TT (median:0.531, IQR:0.496-0.557). The average methylation levels of 12 CpG sites were significantly negative correlated with ΔDAS28 (r = -0.13, P < 0.05). The Logistic regression indicated that combined effect of rs705379, DNA methylation of the PON1 gene (OR (95CI%) = 1.277 (1.003, 1.626)), systemic inflammation index (SIRI) (OR (95CI%) = 1.079 (1.018, 1.143)) served as protective factors on response to LEF in RA patients.The RA patients with SNP-rs705379-CC, the low methylation level of PON1-cg17330251 and more SIRI would be susceptible of response to LEF and more suitable to choose LEF treatment.

    Keywords: rheumatoid arthritis1, Leflunomide2, PON13, DNA methylation4, single nucleotide polymorphism5

    Received: 21 Sep 2024; Accepted: 03 Mar 2025.

    Copyright: © 2025 Zhao, Chen, Liu, Jin, Feng, Dai, Chen, Wang, Yao, Liao, Zhao, Qu, Song and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lingyu Fu, The First Affiliated Hospital of China Medical University, Shenyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more